Generic placeholder image

Recent Patents on Cardiovascular Drug Discovery

Editor-in-Chief

ISSN (Print): 1574-89011
ISSN (Online): 2212-3962

Conivaptan: Potential Therapeutic Implications in Heart Failure

Author(s): Stephen Y. Chen, Zuheir Abrahams, George G. Sokos, Wilfried Mullens, Robert Hobbs, David O. Taylor and Gonzalo V. Gonzalez-Stawinski

Volume 3, Issue 2, 2008

Page: [137 - 140] Pages: 4

DOI: 10.2174/157489008784705403

Price: $65

Abstract

Conivaptan, a dual vasopressin receptor antagonist, is a member of an emerging class of medications for the treatment of euvolemic hyponatremia. These agents induce a free-water diuresis as compared to the natriuretic effect of loop diuretics and make them an intriguing prospect for the treatment of congestive heart failure. Article also includes recent patents on this topic.

Keywords: Conivaptan, aquaretic, vasopressin receptor antagonists, congestive heart failure


Rights & Permissions Print Export Cite as
© 2023 Bentham Science Publishers | Privacy Policy